Ribomic

Ribomic Interest Expense

The Interest Expense of Ribomic (4591.T) as of Oct 30, 2026 is 4.11 M JPY. In the previous year, Interest Expense was 11.71 M JPY — a change of -64.90% (lower).

Interest Expense

4.11 MJPY

YoY

-64.90%

Last updated:

Interest Expense of Ribomic is 2025 4.11 M JPY. Interest Expense of Ribomic was 2024 11.71 M JPY. It decreases by -64.90% lower compared to the previous year.

The Ribomic Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-598,000.00 JPY
Jan 1, 2019
704,000.00 JPY
Jan 1, 2020
993,000.00 JPY
Jan 1, 2021
-8.89 M JPY
Jan 1, 2022
11.31 M JPY
Jan 1, 2023
23.35 M JPY
Jan 1, 2024
11.71 M JPY
Jan 1, 2025
4.11 M JPY
The Ribomic Interest Expense history
YEARInterest ExpenseYoY
4.11 MJPY-64.90%
11.71 MJPY-49.87%
23.35 MJPY+106.48%
11.31 MJPY-227.21%
-8.89 MJPY-995.17%
993,000.00JPY+41.05%
704,000.00JPY-217.73%
-598,000.00JPY-102.91%
20.57 MJPY+1,091.48%
1.73 MJPY-47.90%
3.31 MJPY+201.18%
1.10 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Interest Expense of Ribomic is 4.11 M JPY in 2025.

Interest Expense of Ribomic changed from 11.71 M JPY to 4.11 M JPY, representing a -64.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Ribomic since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Ribomic

All Key Metrics — Ribomic